Metformin – from Devil to Angel

  • Guntram Schernthaner
  • Gerit Holger Schernthaner

Keywords: Metformin, Weight loss, Cardioprotection, First-line Therapy, Insulin Resistance.


Glycaemic Control Migration Inhibitory Factor Insulin Glargine Hepatic Glucose Production Metformin Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574–579.CrossRefPubMedGoogle Scholar
  2. 2.
    Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167–1174.PubMedGoogle Scholar
  3. 3.
    Prager R, Schernthaner G. Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance following metformin treatment. Results of a double-blind cross-over study in type II diabetics. Diabetes 1983;32:1083–1086.CrossRefPubMedGoogle Scholar
  4. 4.
    Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabete Metab 1986;12:346–350.PubMedGoogle Scholar
  5. 5.
    DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294–1301.CrossRefPubMedGoogle Scholar
  6. 6.
    Stumvoll M, Nurjhan N, Perriello G et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550–554.CrossRefPubMedGoogle Scholar
  7. 7.
    Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006; 49:434–441.CrossRefPubMedGoogle Scholar
  8. 8.
    Garber AJ, Duncan TG, Goodman AM et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose response trial. Am J Med 1997;103:491–497.CrossRefPubMedGoogle Scholar
  9. 9.
    DeFronzo RA, Goodman AM. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541–549.CrossRefPubMedGoogle Scholar
  10. 10.
    Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J 1977;2: 1576–1578.CrossRefPubMedGoogle Scholar
  11. 11.
    Schernthaner G, Matthews DR, Charbonnel B et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double blind randomized trial. J Clin Endocrinol Metab 2004;89:6068–6076.CrossRefPubMedGoogle Scholar
  12. 12.
    Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167–74.CrossRefPubMedGoogle Scholar
  13. 13.
    Hanefeld M, Brunetti P, Schernthaner G et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141–147.CrossRefPubMedGoogle Scholar
  14. 14.
    United Kingdom Prospective Diabetes Study (UKPDS) Group. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years (UKPDS 13). Br Med J 1995;310:83–88.Google Scholar
  15. 15.
    Kahn SE, Haffner SM, Heise MA et al. G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–2443.CrossRefPubMedGoogle Scholar
  16. 16.
    Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes? N Engl J Med 2006;355:2477–2480.CrossRefPubMedGoogle Scholar
  17. 17.
    United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865.CrossRefGoogle Scholar
  18. 18.
    Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998;6:47–53.PubMedGoogle Scholar
  19. 19.
    Schultes B, Oltmanns KM, Kern W et al. Modulation of hunger by plasma glucose and metformin. J Clin Endocrinol Metab 2003;88:1133–1141.CrossRefPubMedGoogle Scholar
  20. 20.
    Yasuda N, Inoue T, Nagakura T et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002;298:779–784.CrossRefPubMedGoogle Scholar
  21. 21.
    Lindsay JR, Duffy NA, McKillop AM et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 2005;22:654–657.CrossRefPubMedGoogle Scholar
  22. 22.
    Nathan DM, Buse JB, Davidson MB et al. B. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711–1721.CrossRefPubMedGoogle Scholar
  23. 23.
    Ong CR, Molyneaux LM, Constantino MI et al. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006;29:2361–2364.CrossRefPubMedGoogle Scholar
  24. 24.
    Van Gaal L, Maislos M, Schernthaner G et al. Miglitol combined with metformin improves glycaemic control in type 2 diabetes. Diabetes Obes Metab 2001;3:326–331.CrossRefPubMedGoogle Scholar
  25. 25.
    Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093–1104.CrossRefPubMedGoogle Scholar
  26. 26.
    Wulffele MG, Kooy A, Lehert P et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002;25:2133–2140.CrossRefPubMedGoogle Scholar
  27. 27.
    Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002;25:1691–1698.CrossRefPubMedGoogle Scholar
  28. 28.
    Ahren B, Pacini G, Foley JE et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936–1940.CrossRefPubMedGoogle Scholar
  29. 29.
    DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–1100.CrossRefPubMedGoogle Scholar
  30. 30.
    Strowig SM, Aviles-Santa ML, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 2004;27:1577–1583.CrossRefPubMedGoogle Scholar
  31. 31.
    Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559–569.PubMedGoogle Scholar
  32. 32.
    Rosenstock J, Sugimoto D, Strange P et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29:554–559.CrossRefPubMedGoogle Scholar
  33. 33.
    Dailey GE III, Noor MA, Park JS et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004;116:223–229.CrossRefPubMedGoogle Scholar
  34. 34.
    Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–1289.CrossRefPubMedGoogle Scholar
  35. 35.
    Heine RJ, Diamant M, Mbanya JC et al. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? Br Med J 2006;333:1200–1204.CrossRefGoogle Scholar
  36. 36.
    Evans JM, Ogston SA, Emslie-Smith A et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49930–936.Google Scholar
  37. 37.
    Johnson JA, Simpson SH, Majumdar SR et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244–2248.CrossRefPubMedGoogle Scholar
  38. 38.
    Inzucchi SE, Masoudi FA, Wang Y et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 2005;28:1680–1689.CrossRefPubMedGoogle Scholar
  39. 39.
    Masoudi FA, Inzucchi SE, Wang Y et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583–590.CrossRefPubMedGoogle Scholar
  40. 40.
    Kao J, Tobis J, McClelland RL et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004;93:1347–1350.CrossRefPubMedGoogle Scholar
  41. 41.
    Bowker SL, Majumdar SR, Veugelers P et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254–258.CrossRefPubMedGoogle Scholar
  42. 42.
    Evans JM, Donnelly LA, Emslie-Smith AM et al. Metformin and reduced risk of cancer in diabetic patients. Br Med J 2005;330:1304–1305.CrossRefGoogle Scholar
  43. 43.
    Zakikhani M, Dowling R, Fantus IG et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269–10273.CrossRefPubMedGoogle Scholar
  44. 44.
    Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol 2005;16(Suppl 1):S7–S10.CrossRefPubMedGoogle Scholar
  45. 45.
    Salpeter S, Greyber E, Pasternak G et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;25:CD002967. Review.Google Scholar
  46. 46.
    Holstein A, Stumvoll M. Contraindications can damage your health – is metformin a case in point? Diabetologia 2005;48:2454–2459.CrossRefPubMedGoogle Scholar
  47. 47.
    Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993:16:621–629.CrossRefPubMedGoogle Scholar
  48. 48.
    Nagi DK, Ali VM, Yudkin JS. Effect of metformin on intact proinsulin and des 31, 32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabet Med 1996;13: 753–757.CrossRefPubMedGoogle Scholar
  49. 49.
    Grant PJ. Metformin reduces circulating factor VII concentrations in patients with type 2 diabetes mellitus. Thromb Haemost 1998;80:209–210.PubMedGoogle Scholar
  50. 50.
    Beisswenger PJ, Howell SK, Touchette AD et al. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999;48:198–202.CrossRefPubMedGoogle Scholar
  51. 51.
    Morin-Papunen L, Rautio K, Ruokonen A et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4649–4654.CrossRefPubMedGoogle Scholar
  52. 52.
    Carter AM, Bennett CE, Bostock JA et al. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus. Diabet Med 2005;22:1282–1284.CrossRefPubMedGoogle Scholar
  53. 53.
    Li L, Mamputu JC, Wiernsperger N et al. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 2005;54:2227–2234.CrossRefPubMedGoogle Scholar
  54. 54.
    Stewart MW, Cirkel DT, Furuseth K et al. Effect of metformin plus rosiglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. Diabet Med 2006;23:1069–1078.CrossRefPubMedGoogle Scholar
  55. 55.
    Standeven KF, Ariens RA, Whitaker P et al. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 2002;51:189–197.CrossRefPubMedGoogle Scholar
  56. 56.
    Abbasi F, Chu JW, McLaughlin T et al. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 2004;53:159–164.CrossRefPubMedGoogle Scholar
  57. 57.
    Dandona P, Aljada A, Ghanim H et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004;89:5043–5047.CrossRefPubMedGoogle Scholar
  58. 58.
    De Jager J, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes. J Intern Med 2005;257:100–109.CrossRefPubMedGoogle Scholar
  59. 59.
    Saenz A, Fernandez-Esteban I, Mataix A et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;20:CD002966. Review.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Guntram Schernthaner
    • 1
  • Gerit Holger Schernthaner
    • 2
  1. 1.Rudolfstiftung Hospital-ViennaAustria
  2. 2.University ClinicMedical University ViennaAustria

Personalised recommendations